Muscle Loss: Drugs That Cause It and Drugs That Treat It

Drugs That Cause Muscle Loss

Iatrogenic muscle wasting is underrecognized. Clinicians often attribute progressive weakness to aging or deconditioning when a prescribed medication is the primary driver.

Glucocorticoids represent the single largest pharmacologic contributor to skeletal muscle atrophy. Prednisone doses as low as 7.5 mg/day sustained beyond 3 months activate the ubiquitin-proteasome pathway and suppress mTOR-mediated protein synthesis simultaneously [1]. A systematic review of 14 studies found that 60% of patients on chronic corticosteroids developed measurable proximal muscle weakness, with quadriceps cross-sectional area declining 10-30% within the first year of therapy [2]. The mechanism involves upregulation of MuRF1 and MAFbx/atrogin-1, two muscle-specific E3 ubiquitin ligases that tag myofibrillar proteins for degradation.

Statins produce myalgia in 5-10% of users according to observational data, though the STOMP trial (N=420) found statin-related myalgia rates of only 9.4% vs 4.6% placebo [3]. True structural myopathy with CK elevation above 10x the upper limit of normal occurs in roughly 1 in 10,000 users. Lipophilic statins (simvastatin, atorvastatin) carry higher risk than hydrophilic agents (rosuvastatin, pravastatin) due to greater skeletal muscle penetration. Proposed mechanisms include mitochondrial CoQ10 depletion and impaired prenylation of small GTPases required for myocyte maintenance.

GnRH agonists (leuprolide, goserelin) used in prostate cancer androgen deprivation therapy reduce testosterone to castrate levels, producing 2-4% lean mass loss within the first 12 months of treatment [4]. This is compounded by simultaneous fat gain, creating a sarcopenic obesity phenotype.

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) impair mitochondrial function in connective and muscle tissue. While tendinopathy receives more attention, case series document proximal myopathy persisting months after drug discontinuation [5].

How Glucocorticoid Myopathy Develops

Steroid myopathy follows a predictable proximal-to-distal gradient, affecting hip flexors and shoulder girdle muscles first while sparing facial and respiratory muscles until advanced stages.

The timeline matters clinically. Acute high-dose steroid myopathy (ICU myopathy) can develop within 5-7 days of pulse methylprednisolone combined with neuromuscular blockade. Chronic steroid myopathy from oral prednisone typically becomes clinically apparent at 2-3 months but may remain subclinical for longer in patients who maintain activity levels. Type IIb (fast-twitch glycolytic) fibers are preferentially affected because they express higher concentrations of glucocorticoid receptors than type I oxidative fibers [6].

Diagnosis relies on clinical presentation (painless proximal weakness, preserved CK, characteristic MRI edema pattern) rather than biopsy in most cases. The 2019 American College of Rheumatology guidelines recommend monitoring functional capacity with timed chair-stand tests at each visit for patients on prednisone ≥5 mg/day beyond 3 months [7].

Recovery after dose reduction is slow. Muscle mass restoration typically requires 3-6 months after corticosteroid withdrawal, and some patients never fully recover baseline strength if atrophy was prolonged.

GLP-1 Agonists and Lean Mass: What the Data Show

The rapid weight loss produced by semaglutide and tirzepatide raises legitimate concerns about muscle preservation. Body composition substudies paint a nuanced picture.

In the STEP 1 extension study (N=327 with DXA data), participants on semaglutide 2.4 mg lost 14.9% total body weight at 68 weeks, of which approximately 39% was lean mass [8]. This ratio is consistent with the expected 25-40% lean mass contribution during caloric restriction, though the absolute magnitude of lean loss (roughly 3.5 kg) exceeds what most clinicians consider acceptable in older adults already at sarcopenia risk.

The SURMOUNT-1 trial of tirzepatide showed similar proportional lean mass loss at the 15 mg dose [9]. The critical clinical question is whether this lean mass loss is functionally significant. Grip strength and gait speed data from these trials have not shown proportional functional decline, suggesting that some of the measured "lean mass" loss represents intramuscular water and glycogen rather than contractile protein.

Mitigation strategies during GLP-1 therapy include maintaining protein intake at 1.2-1.6 g/kg/day, progressive resistance training 2-3 times weekly, and considering lower GLP-1 doses with slower titration in patients over 65 or those with baseline low muscle mass. The Endocrine Society's 2024 position statement recommended DXA body composition monitoring for GLP-1 users over 65 [10].

Testosterone and Anabolic Therapies for Muscle Restoration

Testosterone replacement therapy remains the best-studied pharmacologic intervention for muscle loss in hypogonadal men. The evidence base is substantial and the effect sizes are clinically meaningful.

The Testosterone Trials (TTrials, N=790 men aged ≥65 with serum testosterone <275 ng/dL) demonstrated that 12 months of transdermal testosterone gel increased lean mass by 0.9 kg and improved 6-minute walk distance by 33 meters compared to placebo [11]. Larger effect sizes appear in younger hypogonadal men: a meta-analysis of 37 RCTs (N=3,290) found testosterone increased lean body mass by 3.6 kg (95% CI 2.4-4.8) over a median treatment duration of 9 months [12].

The dose-response relationship is well-characterized. Supraphysiologic doses produce greater hypertrophy, but the TRAVERSE trial (N=5,246) established cardiovascular safety only at replacement doses targeting mid-normal range (350-750 ng/dL) [13]. TRAVERSE found no increased MACE risk (HR 0.99 to 95% CI 0.81-1.21) at these physiologic replacement levels.

Nandrolone decanoate has specific evidence in HIV-associated wasting, where 150 mg biweekly increased lean mass by 3.2 kg over 12 weeks in the landmark Strawford et al. trial [14]. It remains used off-label in severe cachexia.

Oxandrolone is FDA-approved for weight regain after involuntary weight loss and produces 2-4 kg lean mass gains in burn patients and chronic disease wasting states. Hepatotoxicity limits long-term use.

Selective Androgen Receptor Modulators (SARMs)

SARMs offer tissue-selective anabolic activity with reduced androgenic effects on prostate and sebaceous glands. None are currently FDA-approved, but several have completed Phase II-III trials.

Enobosarm (GTx-024, ostarine) reached Phase III for cancer cachexia prevention. The POWER trials (POWER 1, N=321; POWER 2, N=320) enrolled patients with non-small cell lung cancer experiencing ≥2% weight loss [15]. Enobosarm 3 mg daily produced statistically significant lean mass gains (approximately 1.5 kg over placebo at 5 months) and met the lean body mass co-primary endpoint but failed to reach statistical significance on the stair-climb power co-primary endpoint in one of the two trials, preventing FDA approval.

Dr. Michael Dobs of Johns Hopkins, principal investigator of the POWER trials, stated: "The lean mass response was consistent and strong, but translating mass gain into functional improvement in advanced cancer patients proved more complex than anticipated."

The selectivity ratio matters. Enobosarm shows approximately 10:1 anabolic-to-androgenic ratio compared to testosterone's 1:1 ratio, meaning prostate stimulation is minimal at muscle-effective doses [16]. This profile could benefit women and older men where androgenic side effects limit testosterone use.

Non-Hormonal Pharmacotherapies Under Investigation

Several non-hormonal drug classes target muscle wasting through distinct molecular pathways. The pipeline is active.

Myostatin inhibitors block the TGF-β superfamily member that functions as a negative regulator of muscle growth. Bimagrumab (a dual ActRII antibody) produced 4.4% lean mass gain in the Phase II RESILIENT trial in sarcopenic older adults but did not improve physical function endpoints sufficiently for approval [17]. A 2024 Phase II trial in obesity (N=180) showed bimagrumab combined with semaglutide preserved lean mass during weight loss while maintaining fat loss equivalent to semaglutide alone.

Anamorelin (a ghrelin receptor agonist) received approval in Japan for cancer cachexia in 2021. The ROMANA trials (ROMANA-1, N=484; ROMANA-2, N=495) showed 1.0-1.5 kg lean mass gains vs. placebo in NSCLC patients with cachexia [18]. Like enobosarm, it gained mass without proportional functional improvement, preventing FDA approval in the United States.

Creatine monohydrate is not a prescription drug but deserves mention as the most evidence-supported supplement for muscle preservation. A Cochrane review of 22 RCTs (N=1,067 older adults) found creatine plus resistance training increased lean mass by 1.37 kg more than resistance training plus placebo over 7-52 weeks [19]. The effect is mediated through phosphocreatine energy buffering and possible upregulation of myogenic regulatory factors.

Beta-hydroxy beta-methylbutyrate (HMB) shows modest anti-catabolic effects. A meta-analysis of 7 RCTs found 3 g/day HMB preserved 0.35 kg more lean mass than placebo during bed rest or caloric restriction [20].

When Drug-Induced Muscle Loss Requires Intervention

Not every patient on a myotoxic medication needs pharmacologic countermeasures. Clinical decision-making depends on baseline muscle reserve, rate of loss, and functional impact.

The 2018 European Working Group on Sarcopenia in Older People (EWGSOP2) criteria provide a diagnostic framework: low muscle strength (grip strength <27 kg men, <16 kg women) confirms probable sarcopenia, while low muscle quantity (appendicular skeletal muscle mass index <7.0 kg/m² men, <5.5 kg/m² women by DXA) confirms the diagnosis [21]. Severe sarcopenia adds low physical performance (gait speed <0.8 m/s or SPPB ≤8).

Dr. Alfonso Cruz-Jentoft, lead author of the EWGSOP2 consensus, noted: "The shift to strength-first screening means clinicians can identify sarcopenia in any office visit using a dynamometer, without waiting for imaging."

Intervention thresholds should be lower when the causative drug cannot be discontinued. A patient requiring chronic prednisone 10 mg/day for polymyalgia rheumatica, for example, should begin structured resistance training immediately and undergo formal sarcopenia screening at 3-month intervals. Testosterone evaluation is warranted in men with both chronic glucocorticoid use and morning total testosterone <300 ng/dL.

Building a Muscle-Preservation Protocol During Necessary Pharmacotherapy

The optimal approach combines resistance exercise, protein optimization, and targeted pharmacotherapy when indicated. Sequence matters.

First-line intervention is always progressive resistance training. A 2020 meta-analysis of 25 RCTs (N=2,267 sarcopenic older adults) found resistance training 2-3 times weekly increased appendicular lean mass by 0.5 kg and leg press strength by 15-25% over 12-24 weeks, regardless of concurrent medications [22]. The minimum effective dose appears to be 2 sessions per week at 60-80% of 1-repetition maximum, with compound movements (squats, deadlifts, rows) producing larger systemic anabolic signaling than isolation exercises.

Protein requirements increase during catabolic stress. The PROT-AGE study group recommends 1.2-1.5 g/kg/day for older adults, rising to 1.5-2.0 g/kg/day during acute illness or active muscle loss [23]. Leucine content matters: 2.5-3.0 g leucine per meal (equivalent to roughly 25-30 g high-quality protein) maximally stimulates muscle protein synthesis through mTORC1 activation.

When resistance training and nutrition prove insufficient (continued functional decline at 3-month reassessment), pharmacotherapy escalation proceeds based on hormonal status, sex, and underlying etiology. Testosterone for documented hypogonadism. Oxandrolone for severe involuntary weight loss. Creatine 3-5 g/day as adjunctive support regardless of other interventions. Vitamin D repletion to 40-60 ng/mL if deficient, as levels below 20 ng/mL independently predict accelerated sarcopenia progression [24].

Drug Interactions That Compound Muscle Risk

Polypharmacy creates multiplicative risk. Certain drug combinations accelerate muscle loss beyond what either agent produces alone.

Glucocorticoids plus fluoroquinolones increase tendon and muscle toxicity risk through convergent mitochondrial impairment. The FDA issued a 2016 boxed warning against this combination when alternatives exist. Statins plus colchicine share CYP3A4 metabolism, and their combination produces myopathy rates 5-10x higher than either drug alone [25]. Proton pump inhibitors reduce magnesium absorption over time, and hypomagnesemia impairs muscle contractile function while also reducing vitamin D activation.

Clinicians should audit medication lists specifically for myotoxic synergism when patients present with unexplained weakness or accelerated functional decline. The Beers Criteria and STOPP/START tools both flag several of these combinations, but neither comprehensively addresses muscle-specific drug interactions.

Monitoring should include serum CK (baseline and every 3-6 months on known myotoxic agents), 25-hydroxyvitamin D, total and free testosterone in men, and serial grip strength measurement using a calibrated Jamar dynamometer at every visit where muscle loss is a concern.